Who are Rebif New Formulation Non Titrated's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Rebif® (clone 484-39), Peginterferon alfa 2, D: Peg-interferon alpha-2a & Ribavirin, low immunogenic interferon-beta-1a, PegIFN alfa-2a, Peginterferon alfa 2 A.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rebif-new-formulation-non-titrated.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Rebif New Formulation Non Titrated — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rebif New Formulation Non Titrated (Rebif New Formulation Non Titrated) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Interferon. Area: Immunology.

phase 3 Interferon IFNAR Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Rebif New Formulation Non Titrated (Rebif New Formulation Non Titrated) — EMD Serono. Rebif New Formulation Non Titrated is an interferon beta-1a formulation used to treat multiple sclerosis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Rebif New Formulation Non Titrated TARGET	Rebif New Formulation Non Titrated	EMD Serono	phase 3	Interferon	IFNAR
Rebif® (clone 484-39)	Rebif® (clone 484-39)	Merck KGaA, Darmstadt, Germany	marketed	Interferon beta-1a	Type I interferon receptor (IFNAR)
Peginterferon alfa 2	Peginterferon alfa 2	Dr. Conrado Fernandez	marketed	Interferon alpha	Interferon-alpha receptor (IFNAR)
D: Peg-interferon alpha-2a & Ribavirin	D: Peg-interferon alpha-2a & Ribavirin	Kaohsiung Medical University Chung-Ho Memorial Hospital	marketed	Antiviral combination therapy	Interferon-alpha receptor (IFNAR); viral RNA-dependent RNA polymerase
low immunogenic interferon-beta-1a	low immunogenic interferon-beta-1a	Biogen	marketed	Interferon-beta	Interferon-beta receptor (IFNAR)
PegIFN alfa-2a	PegIFN alfa-2a	The Second Affiliated Hospital of Chongqing Medical University	marketed	Pegylated interferon alpha	Interferon-alpha receptor (IFNAR)
Peginterferon alfa 2 A	Peginterferon alfa 2 A	Dr. Conrado Fernandez	marketed	Interferon alpha	Interferon-alpha receptor (IFNAR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Interferon class)

EMD Serono · 3 drugs in this class
Cinnagen · 2 drugs in this class
Tanabe Pharma Corporation · 2 drugs in this class
Biogen · 1 drug in this class
Celgene · 1 drug in this class
EMD Serono Research & Development Institute, Inc. · 1 drug in this class
Case Comprehensive Cancer Center · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class
Human Genome Sciences Inc. · 1 drug in this class
Bayer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rebif New Formulation Non Titrated — Competitive Intelligence Brief. https://druglandscape.com/ci/rebif-new-formulation-non-titrated. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab